Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Long term follow-up of the STOPAGO study

Blood blood.2024025707.

https://doi.org/10.1182/blood.2024025707

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Stefan Djordjevic, Delphine Lebon, Raphael Itzykson, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Nicolas Duployez, Jean Pierre Marolleau, Loïc Garçon, Thomas Boyer

Blood (2023) 142 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2023-179276

Published: 2023

Journal Articles

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Hélène Kemp, Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, Etienne Paubelle, Magalie Joris, Amandine Charbonnier, Lydia Montes, Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel

Blood (2023) 142 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2023-190177

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study

Blood (2023) 141 (23): 2867–2877.

https://doi.org/10.1182/blood.2022018665

Published: 2023

Includes: Supplemental data

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Blood (2022) 140 (Supplement 1): 112–114.

https://doi.org/10.1182/blood-2022-157903

Published: 2022

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Journal Articles

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Blood (2022) 139 (15): 2338–2346.

https://doi.org/10.1182/blood.2021013526

Published: 2022

Includes: Supplemental data

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Audrey DA Rocha, Alexis Caulier, Magalie Joris, Amandine Charbonnier, Mathieu Sage, Lavinia Merlusca, Lydia Montes, Nicolas Guillaume, Judith Desoutter, Marie-Noëlle Lacassagne, Marine Quint, Thomas Boyer, Véronique Harrivel, Nicolas Duployez, Alice Marceau, Jean-Pierre Marolleau, Delphine Lebon

Blood (2021) 138 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2021-145523

Published: 2021

Journal Articles

Rate of Prolonged Response after Stopping Thrombopoietin-Receptor Agonists Treatment in Primary Immune Thrombocytopenia (ITP): Results from a Nationwide Prospective Multicenter Interventional Study (STOPAGO)

Blood (2021) 138 (Supplement 1): 583.

https://doi.org/10.1182/blood-2021-152767

Published: 2021

Journal Articles

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Blood (2021) 138 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2021-148270

Published: 2021

Journal Articles

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

Blood (2021) 138 (Supplement 1): 215.

https://doi.org/10.1182/blood-2021-150705

Published: 2021

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137012

Published: 2020

NARROW

Long term follow-up of the STOPAGO study

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Impact of Residence in an Agricultural Zone on AML Characteristics

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Rate of Prolonged Response after Stopping Thrombopoietin-Receptor Agonists Treatment in Primary Immune Thrombocytopenia (ITP): Results from a Nationwide Prospective Multicenter Interventional Study (STOPAGO)

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only